- 1 Symptoms at presentation for patients admitted to hospital with
- 2 Covid-19: results from the ISARIC prospective multinational
- ³ observational study

4	
5	Authors
6	ISARIC Clinical Characterisation Group *
7	
8	* Members listed at end of manuscript
9	
10	Keywords
11	Covid-19, SARS-CoV-2, symptoms, diagnosis, case definition
12	
13	Running title
14	Covid-19 symptoms at hospital admission
15	
16	Correspondence to
17	Dr Mark G Pritchard
18	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
19	Oxford, Oxford, UK
20	mark.pritchard@ndm.ox.ac.uk
21	
22	Alternate corresponding author
23	Professor Piero L Olliaro
24	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 25 Oxford, Oxford, UK
- 26 piero.olliaro@ndm.ox.ac.uk
- 27
- 28 Summary
- 29 Typical symptoms of fever, cough and shortness of breath are less common in people admitted to
- 30 hospital with Covid-19 toward extremities of age. Published case definitions appear less sensitive
- 31 toward extremes of age, and atypical symptoms need to be recognised.

32

34 Abstract

35 Background

36 Symptom recognition is necessary to identify people with possible Covid-19. Clinical case definitions

37 vary in type and number of symptoms included. No large studies have investigated how these

38 perform for hospitalized patients of different ages and sex.

39 Methods

40 We used international prospective observational data from patients admitted to hospital with

41 laboratory-confirmed Covid-19. We investigated how symptoms varied by age and sex. We

42 performed logistic regression to assess the relationship of age and sex with the most prevalent

43 symptoms in our dataset and with published case definitions, allowing for clustering by country as a

44 random intercept.

45 Results

46 60 161 patients from 43 countries were included, with median age 70 years (interquartile range 55-47 82). Fever (68%), cough (68%) and shortness of breath (63%) were the most prevalent symptoms. 48 Their prevalence was greater among patients aged 30–60 years (respectively 79%, 78%, 66%), and 49 lower in children (\leq 18 years: 68%, 47%, 22%) and older adults (\geq 70 years: 61%, 62%, 61%). The most 50 sensitive case definition assessed was one or more of cough, shortness of breath, fever, muscle 51 pains or sore throat, met by 92% of the whole cohort. Confusion was the most prevalent symptom 52 for patients whose symptoms did not meet any of the assessed case definitions. Regression models 53 showed significant differences in symptoms with age, and considerable heterogeneity between 54 countries.

55 Conclusions

Older adults and children admitted to hospital with Covid-19 are less likely to present with typical
symptoms of cough, fever and shortness of breath. Vigilance for atypical symptoms towards
extremities of age increases sensitivity of identifying Covid-19.

59 Background

For emerging infectious diseases, knowledge of symptoms is vital to identify people with possible infection and follow-up actions [1]. Details of exposures, symptoms, signs and investigations are combined into case definitions to classify suspected, probable and confirmed cases. These can be used for disease surveillance, to guide public health actions, and case management. In settings without microbiological testing, these criteria may be used to reach a clinical diagnosis; in settings where testing is available they may be used to guide testing strategies [2].

66 Covid-19 emerged in December 2019, caused by the severe acute respiratory syndrome 67 coronavirus-2 (SARS-CoV-2) [3, 4]. The most frequently reported symptoms were fever, cough and shortness of breath, together with a range of less frequent symptoms [4-8]. Altered sense of taste 68 69 and smell have been found to be strongly associated with Covid-19 [2, 9, 10]. The World Health 70 Organization (WHO) surveillance case definition (used by the European and African Centres for 71 Disease Control) for people who have been in a location with community transmission of Covid-19 requires fever and at least one sign or symptom of respiratory disease, such as cough or shortness of 72 breath [11]. The Centers for Disease Control and Prevention in the United States provides a non-73 74 exhaustive list of respiratory, enteric and constitutional symptoms: fever or chills, cough, shortness 75 of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, 76 sore throat, congestion or runny nose, nausea or vomiting, and diarrhoea [12]. Public Health 77 England's definition of a possible Covid-19 case in the community is any one of new continuous 78 cough, high temperature, or change to sense of taste or smell [13]. For inpatients, their definition is 79 evidence of pneumonia, acute respiratory distress syndrome, or one of two clusters of symptoms: 80 fever with at least one of cough, hoarseness, nasal discharge or congestion, shortness of breath, 81 sore throat, wheezing or sneezing; or any change in sense of taste of smell [13]. 82 Despite Covid-19's status as a pandemic, large reports of clinical characteristics have so far

been limited to cohorts from China, Europe and the United States [14]. There have also been no
reports of differences in symptoms according to age or sex from large cohorts. Our primary

85 objective was to investigate how symptoms of patients admitted to hospital with confirmed Covid-

86 19 vary by age and sex. Secondarily we aimed to investigate how sensitivity of clinical case

87 definitions varied among these populations, and to explore heterogeneity between countries.

88 Methods

89 Study design and setting

90 This analysis used international observational data of clinical features of patients admitted to hospital with Covid-19 between 30 January and 3 August 2020. The International Severe Acute 91 Respiratory and emerging Infection Consortium (ISARIC)/WHO Clinical Characterisation Protocol for 92 93 Severe Emerging Infections is a standardized protocol for investigation of severe acute infections by 94 pathogens of public health interest [15]. The ISARIC case report forms [16] allow standardized data 95 collection from the start of an outbreak and rapid dissemination of clinical information [4, 17-21]. 96 Different tiers of data collection exist to allow sites to collect data to the highest possible standards 97 while recognising varying levels of resource for data collection during epidemics. Details of symptoms at admission were included on the case report forms for all tiers. Data were collected via 98 electronic 'Core' and 'Rapid' forms by the ISARIC Clinical Characterisation Group, and through 99 100 aligned forms by ISARIC-4C Coronavirus Clinical Characterisation Consortium in the United Kingdom 101 [22] and the COVID-19 Critical Care Consortium [23]. Investigators from 41 countries are using 102 Research electronic Data Capture (REDCap, version 8.11.11, Vanderbilt University, Nashville, Tenn.) 103 to contribute their data to a central database hosted by the University of Oxford. Additional data 104 were submitted by investigators from Malaysia, Russia [24] and Spain, who were not using the 105 University of Oxford REDCap instance. All investigators retained full rights to their data.

106 Study population

Patients of any age admitted to hospital with suspected or confirmed Covid-19 were eligible for
 recruitment. Some versions of the case report form included specific criteria such as fever and
 cough, but investigators were able to include patients with a clinical suspicion of Covid-19 even if

- 110 these criteria were not met. This analysis was limited to patients who were admitted to hospital
- 111 with symptomatic laboratory-confirmed Covid-19, according to sites' local diagnostic methods. We
- 112 excluded asymptomatic patients who had been admitted to hospital for isolation and patients
- admitted for other conditions who subsequently developed Covid-19 symptoms.
- 114 Variables and measurement
- 115 Variables used in this analysis were age, sex at birth, symptoms, date of symptoms onset, SARS-CoV-
- 116 2 confirmation, and country of recruitment. To allow proportions to be calculated with a reliable
- denominator, only symptoms prespecified on the case report forms [16, 22, 23] were included in this
- analysis. The list of symptoms collected is presented with the results.
- **119** Ethical considerations
- 120 This observational study required no change to clinical management and permitted enrolment in
- 121 other research. The study was approved by the World Health Organization Ethics Review Committee
- 122 (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site
- 123 according to local requirements.

124 Statistical methods

- 125 Data were converted to Study Data Tabulation Model (version 1.7, Clinical Data Interchange
- 126 Standards Consortium, Austin, Tex.) to allow inclusion of data submitted not using the ISARIC case
- 127 report forms. We excluded patients with all symptoms recorded as missing or unknown, and those
- 128 with missing age, sex, country or onset date.

Continuous variables were expressed as median with interquartile range, and categorical
variables as counts with percentages. We tested for differences between female and male patients
using Wilcoxon rank-sum tests for continuous variables and chi-square tests for categorical variables.
We grouped patients into ten-year age bands (with a single group for age ≥90 years). We plotted
the most frequently reported symptoms by age group, presenting missing data as a third category.

134 We collated symptoms according to four sets of clinical criteria, based on published case definitions

135 [11-13]:

136 1. Fever plus at least one of cough or shortness of breath;

137 2. Fever plus at least one of cough, nasal discharge, shortness of breath, sore throat, or

138 wheeze;

139 3. Either cough or fever;

140 4. One or more of cough, shortness of breath, fever, muscle pains, or sore throat.

141 (Altered senses of smell and taste were not included in these classifications as they were not

included on all versions of the case report forms so had high levels of missingness.) Patients with

143 missing details of any symptoms included in these criteria were omitted from the composite groups.

144 We plotted proportions of patients meeting each set of criteria by ten-year age group, with 95%

145 confidence intervals (CI) calculated using the Clopper–Pearson method.

146 We used logistic regression to identify associations of age and sex with the twelve most 147 prevalent symptoms. Age group and sex were included as fixed effects, with country as a random 148 intercept. To display heterogeneity between countries on the same scale as the fixed effects, we calculated median odds ratios (MOR) [25]. This quantifies variation between countries by comparing 149 odds of an outcome between randomly chosen persons in different clusters who share the same 150 151 covariates [25]. MORs are defined as a comparison of the group with greater propensity to the 152 group with lower propensity, so lie in the range 1 to infinity [25]. We plotted the MOR to show the 153 magnitude of the effect of heterogeneity and allow comparison with the fixed effects in our data. 154 79% of patients were recruited in a single country. As a sensitivity analysis, we repeated the analysis excluding patients from this country to see if results substantially changed. Finally, we 155 156 plotted age-stratified symptom frequencies for each country with at least 250 patients. No minimum sample size was calculated. All significance tests were two-tailed. Analyses 157 158 were performed using R (version 3.6.2, R Foundation for Statistical Computing, Vienna, Austria) with 159 packages including binom, Epi, ggplot2, Ime4, sistats, tableone, and tidyverse.

160 Results

- 161 Data were available for 99 623 patients. We excluded 24 336 who did not have documented SARS-
- 162 CoV-2 confirmation, 2583 with missing data, and 5828 who developed Covid-19 after admission to
- hospital. 6715 (9.6%) were admitted to hospital with a diagnosis of asymptomatic Covid-19. The
- 164 greatest proportion of asymptomatic patients was in the age-band 10–20 years (46%,
- 165 Supplementary Figure 1). The greatest proportion of asymptomatic patients was in Malaysia (49%),
- 166 where hospitalization was compulsory throughout the data collection period for people with Covid-
- 167 19. After excluding asymptomatic patients, 60 161 patients remained in the dataset (Figure 1).
- 168 Included patients were recruited from 394 sites in 43 countries (Supplementary Table 1). 47 332
- 169 (79%) patients were included from the United Kingdom.

The median age of included patients was 70 years (interquartile range [IQR] 54–82; Table 1). 930 (1.5%) were 18 years or younger. Of those older than 18 years, the median age was 70 years (IQR 55–82). The age distribution of patients varied among countries, between a median of 10 years in Poland, where a large proportion of included patients were children, and 73 years in the United Kingdom (Supplementary Figure 2). 34 674 (58%) patients were male.

175 The most frequently reported symptoms were fever, cough and shortness of breath (Table 176 2). Fever, cough and shortness of breath were each significantly more prevalent in male patients, whereas less typical symptoms such as confusion, nausea and vomiting, diarrhoea, chest pain, 177 178 headache and abdominal pain were more prevalent in female patients. The greatest sex-related 179 difference was for nausea and vomiting, reported by 20% of female patients but only 14% of male 180 patients. For most symptoms, the greatest prevalence was reported in adults aged between 30 and 181 60 years, decreasing toward extremities of age (Figure 2). Frequency of fatigue and confusion 182 increased with age. Large numbers of patients had missing data for anorexia, severe dehydration, 183 altered sense of taste and smell, and inability to walk as these were not included on all case report 184 forms. Excluding these symptoms, few patients had missing data for the most prevalent symptoms. Data on symptoms included in the composite criteria were missing for 314 patients. The 185

186 clinical criteria were calculated for the remaining 59 847 participants. Each set of criteria was met by 187 a greater proportion of patients aged 30 to 60 years than toward either extreme of age (Figure 3). 188 The criteria of fever plus at least one of cough or shortness of breath was met by 35 394 (59%) patients, but only 37% of those aged 18 years and under, and 51% of those aged 70 years or over. 189 190 The most sensitive criteria were one or more of cough, shortness of breath, fever, muscle pains, or 191 sore throat, met by 55 198 (92%) participants. These criteria were met by 89% aged 18 years and 192 under, and 89% of those aged 70 years or over. Each set of criteria were met by a greater 193 proportion of male than female patients (Table 2). 194 For the 4649 patients whose symptoms did not meet any of the assessed case definitions, 195 the most frequent symptom was confusion (49%; Table 3). This rose with age to 67% of those aged

90 years or older. Nausea and vomiting, and abdominal pain were the most common symptoms forpeople less than 70 years old who did not meet any of the case definitions.

198 In the logistic regression models (Figure 4), similar associations between age and symptoms 199 were seen after adjustment for sex and relationship of onset to admission date as in the unadjusted 200 bar charts. Confusion increased with age. Nausea and vomiting, headache, abdominal pain, and 201 sore throat were each more frequent in younger age groups, decreasing with age. The 95% CI for 202 sex excluded one for most symptoms, but the point estimate was close to one for most. In these 203 analyses, male patients had greater odds of fever, cough and shortness of breath, and lower odds of 204 gastrointestinal symptoms of nausea and vomiting, diarrhoea, abdominal pain, chest pain, headache 205 and sore throat. The median odds ratio for heterogeneity between countries was greater than the 206 relationship with sex in all symptoms. It was of similar magnitude to the relationship with age for 207 most symptoms. For each symptom, heterogeneity between countries was of a similar magnitude to 208 the effect of age, and a greater magnitude than sex.

When we repeated the analysis excluding patients from the United Kingdom, the patterns of symptoms were similar to the main analysis (Supplementary Figure 3). The peak prevalence of fever, cough and shortness of breath was in 70- to 80-year-olds, and fatigue increased with age. This

resulted in a change to the calculated sensitivity of the clinical case definitions. Below the age of 50
years, each was less sensitive in the analysis excluding the United Kingdom than in the analysis
including it; above the age of 70 years each was more sensitive (grey lines in Figure 3). Within
countries, the baseline prevalence of each symptom varied but patterns within countries were
broadly similar to the overall results (Supplementary figures 4–15).

217 Discussion

In this large, multinational cohort, we found that symptoms for people admitted to hospital with
Covid-19 varied by age and sex. Typical symptoms of fever, cough and shortness of breath were
each more prevalent between the ages of 30 and 60 years. Commonly used clinical case definitions
identified greater proportions of patients between the ages of 30 and 60 years, and fewer in
childhood and older age.

223 This is the first large assessment of Covid-19 symptoms by age. The presence of atypical 224 symptoms in older adults has been recognised [26] but not evaluated in a large international cohort. 225 Liu and colleagues [27] found similar distributions of symptoms between older and younger patients 226 with Covid-19, but their older cohort had a median age of 68 years, which is younger than the 227 median age of our total cohort. The finding of atypical presentations among older patients with 228 Covid-19 correlates with similar findings of atypical presentations for pneumonia, bacteraemia and coronary artery disease [28, 29]. Lower prevalence of symptoms in children and young people has 229 230 been recognised [30, 31], but no large international cohorts collecting data systematically from both 231 adults and children been reported. Separate analyses on the ISARIC-4C data have identified clustering of symptoms in children [32] and adults [33]. In each, fever, cough and shortness of 232 233 breath clustered as frequently co-occurring symptoms [32, 33]. In children, the next most frequent 234 cluster consisted of systemic, enteric and mucocutaneous symptoms [32]; for adults, other clusters 235 consisted of non-specific viral symptoms, gastrointestinal symptoms, upper respiratory symptoms, 236 neurological symptoms, and symptoms of bronchospasm [33]. These data were included in this

237 global dataset so the results of these analyses are not independent of our results.

The differences in symptoms by sex were statistically significant but generally of small magnitude. Adjusted for sex and country, the common symptoms of fever, cough and shortness of breath were more common in male patients, whereas all other symptoms were equal or more common in female patients. A cohort of non-hospitalized patients with Covid-19 in Poland found greater differences in symptoms of lack of appetite (55% of women, 36% of men) and taste disorder (53% women, 40% men) [34].

244 Our results suggest considerable heterogeneity among countries. We have not attempted 245 to elicit reasons for heterogeneity, which may include differences in how patients present to 246 hospital, how they describe their symptoms, and hospitals' criteria for admission and testing. It might also reflect differential recruitment to the study, as sites in some countries were unable to 247 248 recruit confused patients due to requirements for consent, whereas in other countries the 249 requirement for consent had been waived or assent could be obtained from a proxy. An 250 international review of reported Covid-19 symptoms [14] found substantial variation. We explored 251 the effect of this heterogeneity in the regression models using country as a random effect, and by repeating the analysis excluding the largest country. Each suggested an underlying pattern of lower 252 frequencies of typical symptoms in children and older adults. Therefore, although the prevalence of 253 254 each symptom reported in this study may not generalize to all settings, we have evidence to support 255 the need to be alert to age-dependent differences across countries.

The size of this cohort is a strength. However, more than 80% of patients were recruited in a single country, and less than 1% of patients were recruited from lower-middle or low-income countries. The cohort also represents older age groups better than young ones, with only 1.8% of the cohort aged 18 years or younger. Combined with the known heterogeneity between countries, this limits the generalizability of estimates of symptom prevalence. More broadly, there is a shortage of information to guide practice outside high-income countries: a recent scoping review of clinical characteristics of Covid-19 identified no large cohorts in non-high-income countries except

263 China [14].

264 This analysis included only patients who were admitted to hospital and tested for SARS-CoV-2. This patient population is more likely to be severely unwell and more likely to exhibit symptoms 265 typically associated with Covid-19 than people who are being managed in the community or whose 266 disease has not been recognised. This might suggest that the reporting of 'typical' Covid-19 267 268 symptoms in this cohort is likely to be an overestimate of the population prevalence. Symptoms 269 associated with less severe disease might be underestimated in this cohort. Symptoms are 270 subjective and cannot be externally verified. Some differences for children may reflect that 271 symptoms could only be recorded if a caregiver recognised the symptom or the child had the 272 appropriate vocabulary to describe it. Similarly, some symptoms may be under-reported in elderly 273 patients if there are difficulties in communication, for example due to delirium. 274 The absence of a control group of patients without Covid-19 in this dataset prevented 275 estimation of specificity or positive and negative predictive values. This prevents us from advocating 276 changes to clinical case definitions, as such decisions inevitably require a balance of false-positive 277 and false-negative rates. 278 Our results suggest that reliance on clinical case definitions may result in missing cases of 279 Covid-19, especially among children and older adults. While healthcare professionals assessing 280 patients can make a broader assessment of a patient's condition, non-healthcare professionals 281 making decisions regarding isolation or exclusion from activities may adhere to the criteria more 282 strictly. Reported prevalence of Covid-19 may also rely on strict interpretation of case definitions. In 283 settings where comprehensive contact tracing is planned, or there is easy access to microbiological 284 testing, a highly sensitive case definition is desirable. However, where decisions are based on clinical 285 diagnoses, it is important to recognise other pathogens that can cause similar constellations of symptoms. This is particularly important if a treatment could be offered for an alternative diagnosis, 286 such as influenza. Addition of symptoms such as confusion or gastrointestinal symptoms to the 287 288 Covid-19 case definition could increase sensitivity, but at a cost of reduced specificity. Changes in

the senses of taste and smell have recently been added to case definitions. Our data suggest that
these criteria would detect only a small proportion of patients admitted to hospital with Covid-19
who were not included by other definitions.

292 These results highlight the need to consider Covid-19 even if individuals do not display 293 typical symptoms of the disease. This is especially the case in children and older adults. Given that 294 our results are likely to overestimate the sensitivity of the clinical criteria currently used to identify 295 patients for SARS-CoV-2 testing, our results suggest a lower limit to the proportion of people in the 296 community with Covid-19 who would not be identified. Addition of confusion as a symptom would 297 increase the sensitivity of case definitions for older adults; and inclusion of nausea and vomiting or 298 abdominal pain would increase sensitivity for children and young adults. The high proportion of 299 asymptomatic patients identified in patients aged 10 to 30 years, in spite of this cohort not being 300 eligible for hospital admission in many countries, suggests that universal screening in these ages 301 could be beneficial when there is widespread community circulation of Covid-19. Ongoing data 302 collection outside high-income countries is needed to establish whether alternative case definitions 303 are needed in different settings. Work is also ongoing to determine whether some constellations of 304 symptoms are associated with better or poorer outcomes than others.

305 ISARIC Clinical Characterisation Group

306 Sheryl Ann Abdukahil, Ryuzo Abe, Laurent Abel, Lara Absil, Andrew Acker, Shingo Adachi, Elisabeth 307 Adam, Diana Adrião, Kate Ainscough, Ali Ait Hssain, Younes Ait Tamlihat, Takako Akimoto, Tala Al-308 Dabbous, Abdulrahman Al-Fares, Eman Al Qasim, Razi Alalqam, Beatrice Alex, Kévin Alexandre, Huda 309 Alfoudri, Kazali Enagnon Alidinou, Jeffrey Aliudin, Clotilde Allavena, Nathalie Allou, João Alves, Rita 310 Alves, Maria Amaral, Heidi Ammerlaan, Phoebe Ampaw, Roberto Andini, Claire Andrejak, Andrea 311 Angheben, François Angoulvant, Séverine Ansart, Massimo Antonelli, Carlos Alexandre Antunes De 312 Brito, Yaseen Arabi, Irene Aragao, Antonio Arcadipane, Lukas Arenz, Jean-Benoît Arlet, Christel 313 Arnold-Day, Lovkesh Arora, Elise Artaud-Macari, Angel Asensio, Jean Baptiste Assie, Anika Atique,

314 Johann Auchabie, Hugues Aumaitre, Laurène Azemar, Cécile Azoulay, Benjamin Bach, Delphine 315 Bachelet, J. Kenneth Baillie, Erica Bak, Agamemnon Bakakos, Firouzé Banisadr, Renata Barbalho, 316 Wendy S. Barclay, Michaela Barnikel, Audrey Barrelet, Cleide Barrigoto, Romain Basmaci, Diego 317 Fernando Bautista Rincon, Alexandra Bedossa, Sylvie Behilill, Aleksandr Beljantsev, David Bellemare, 318 Anna Beltrame, Marine Beluze, Nicolas Benech, Dehbia Benkerrou, Suzanne Bennett, Luís Bento, 319 Jan-Erik Berdal, Delphine Bergeaud, Lorenzo Bertolino, Simon Bessis, Sybille Bevilcaqua, Krishna 320 Bhavsar, Felwa Bin Humaid, François Bissuel, Patrick Biston, Laurent Bitker, Pablo Blanco-Schweizer, 321 Mathieu Blot, Filomena Boccia, Debby Bogaert, François Bompart, Gareth Booth, Diogo Borges, 322 Raphaël Borie, Jeannet Bos, Hans Martin Bosse, Elisabeth Botelho-Nevers, Lila Bouadma, Olivier 323 Bouchaud, Sabelline Bouchez, Dounia Bouhmani, Damien Bouhour, Kévin Bouiller, Laurence Bouillet, 324 Camille Bouisse, Anne-Sophie Boureau, Maude Bouscambert, Jason Bouziotis, Bianca Boxma, 325 Marielle Boyer-Besseyre, Maria Boylan, Cynthia Braga, Timo Brandenburger, Luca Brazzi, Dorothy 326 Breen, Patrick Breen, Kathy Brickell, Nicolas Brozzi, Nina Buchtele, Christian Buesaguillo, Polina 327 Bugaeva, Marielle Buisson, Erlina Burhan, Ingrid G. Bustos, Denis Butnaru, Sheila Cárcel, André 328 Cabie, Susana Cabral, Eder Caceres, Mia Callahan, Kate Calligy, Jose Andres Calvache, João Camões, 329 Valentine Campana, Paul Campbell, Cecilia Canepa, Mireia Cantero, Pauline Caraux-Paz, Filipa 330 Cardoso, Filipe Cardoso, Sofia Cardoso, Simone Carelli, Nicolas Carlier, Gayle Carney, Chloe 331 Carpenter, Marie-Christine Carret, François Martin Carrier, Gail Carson, Maire-Laure Casanova, 332 Mariana Cascão, José Casimiro, Bailey Cassandra, Silvia Castañeda, Nidyanara Castanheira, Guylaine 333 Castor-Alexandre, Henry Castrillón, Ivo Castro, Ana Catarino, François-Xavier Catherine, Roberta 334 Cavalin, Giulio Giovanni Cavalli, Alexandros Cavayas, Adrian Ceccato, Minerva Cervantes-Gonzalez, 335 Anissa Chair, Catherine Chakveatze, Adrienne Chan, Meera Chand, Julie Chas, Camille Chassin, 336 Anjellica Chen, Yih-Sharng Chen, Matthew Pellan Cheng, Antoine Cheret, Thibault Chiarabini, Julian 337 Chica, Catherine Chirouze, Davide Chiumello, Hwa Jin Cho, Sung Min Cho, Bernard Cholley, Jose 338 Pedro Cidade, Jose Miguel Cisneros Herreros, Barbara Wanjiru Citarella, Anna Ciullo, Jennifer Clarke, 339 Sara Clohisey, Cassidy Codan, Caitriona Cody, Alexandra Coelho, Gwenhaël Colin, Michael Collins,

340 Sebastiano Maria Colombo, Pamela Combs, JP Connelly, Marie Connor, Anne Conrad, Sofía 341 Contreras, Graham S. Cooke, Mary Copland, Hugues Cordel, Amanda Corley, Sarah Cormican, Sabine 342 Cornelis, Arianne Joy Corpuz, Grégory Corvaisier, Camille Couffignal, Sandrine Couffin-Cadiergues, Roxane Courtois, Charles Crepy D'Orleans, Sabine Croonen, Gloria Crowl, Jonathan Crump, Claudina 343 344 Cruz, Marc Csete, Alberto Cucino, Caroline Cullen, Matthew Cummings, Gerard Curley, Elodie Curlier, 345 Paula Custodio, Frédérick D'Aragon, Ana Da Silva Filipe, Charlene Da Silveira, Eric D'Ortenzio, Al-346 Awwab Dabaliz, Heidi Dalton, Jo Dalton, Nick Daneman, Emmanuelle A. Dankwa, Jorge Dantas, 347 Nathalie De Castro, Diego De Mendoza, Rafael Freitas De Oliveira França, Rosanna De Rosa, Thushan 348 De Silva, Peter De Vries, David Dean, Marie-Pierre Debray, William Dechert, Lauren Deconninck, 349 Romain Decours, Isabelle Delacroix, Karen Delavigne, Ionna Deligiannis, Andrea Dell'amore, Pierre 350 Delobel, Elisa Demonchy, Emmanuelle Denis, Dominique Deplangue, Dominique Deplangue, Pieter 351 Depuydt, Mehul Desai, Diane Descamps, Mathilde Desvallée, Santi Rahayu Dewayanti, Alpha Diallo, 352 Sylvain Diamantis, André Dias, Juan Jose Diaz Diaz, Rodrigo Diaz, Kévin Didier, Jean-Luc Diehl, Wim 353 Dieperink, Jérôme Dimet, Vincent Dinot, Alphonsine Diouf, Yael Dishon, Félix Djossou, Annemarie B. 354 Docherty, Andy Dong, Christl A. Donnelly, Maria Donnelly, Chloe Donohue, Céline Dorival, James 355 Joshua Douglas, Renee Douma, Nathalie Dournon, Triona Downer, Mark Downing, Tom Drake, 356 Vincent Dubee, François Dubos, Alexandra Ducancelle, Susanne Dudman, Jake Dunning, Emanuele 357 Durante Mangoni, Silvia Duranti, Lucian Durham III, Bertrand Dussol, Xavier Duval, Anne Margarita 358 Dyrhol-Riise, Carla Eira, José Ernesto Vidal, Mohammed El Sanharawi, Subbarao Elapavaluru, Brigitte 359 Elharrar, Natalie Elkheir, Jacobien Ellerbroek, Rachael Ellis, Philippine Eloy, Tarek Elshazly, Isabelle 360 Enderle, Ilka Engelmann, Vincent Enouf, Olivier Epaulard, Mariano Esperatti, Hélène Esperou, Marina 361 Esposito-Farese, João Estevão, Manuel Etienne, Manuel Etienne, Nadia Ettalhaoui, Anna Greti 362 Everding, Mirjam Evers, Isabelle Fabre, Amna Faheem, Arabella Fahy, Cameron J. Fairfield, Pedro 363 Faria, Nataly Farshait, Arie Zainul Fatoni, Karine Faure, Mohamed Fayed, Niamh Feely, Jorge 364 Fernandes, Marília Fernandes, Susana Fernandes, Joana Ferrão, Eglantine Ferrand Devouge, Mário 365 Ferraz, Benigno Ferreira, Ricard Ferrer-Roca, Claudia Figueiredo-Mello, Clara Flateau, Tom Fletcher,

366 Letizia Lucia Florio, Claire Foley, Victor Fomin, Claudio Duarte Fonseca, Tatiana Fonseca, Patricia 367 Fontela, Simon Forsyth, Giuseppe Foti, Erwan Fourn, Rob Fowler, Diego Franch-Llasat, Christophe 368 Fraser, John Fraser, Marcela Vieira Freire, Ana Freitas Ribeiro, Caren Friedrich, Stéphane Fry, Nora 369 Fuentes, Masahiro Fukuda, Joan Gómez-Junyent, Valérie Gaborieau, Benoît Gachet, Rostane Gaci, 370 Massimo Gagliardi, Jean-Charles Gagnard, Amandine Gagneux-Brunon, Sérgio Gaião, Phil Gallagher, 371 Elena Gallego Curto, Carrol Gamble, Arthur Garan, Esteban Garcia-Gallo, Rebekha Garcia, Denis 372 Garot, Valérie Garrait, Nathalie Gault, Aisling Gavin, Alexandre Gaymard, Johannes Gebauer, Louis 373 Gerbaud Morlaes, Nuno Germano, Jade Ghosn, Marco Giani, Carlo Giaguinto, Jess Gibson, Tristan 374 Gigante, Morgane Gilg, Guillermo Giordano, Michelle Girvan, Valérie Gissot, Gezy Giwangkancana, 375 Daniel Glikman, Petr Glybochko, Eric Gnall, Geraldine Goco, François Goehringer, Siri Goepel, Jean-376 Christophe Goffard, Jonathan Golob, Isabelle Gorenne, Cécile Goujard, Tiphaine Goulenok, Margarite 377 Grable, Edward Wilson Grandin, Pascal Granier, Giacomo Grasselli, Christopher A. Green, William 378 Greenhalf, Segolène Greffe, Domenico Luca Grieco, Matthew Griffee, Fiona Griffiths, Ioana Grigoras, 379 Albert Groenendijk, Anja Grosse Lordemann, Heidi Gruner, Yusing Gu, Jérémie Guedj, Dewi Guellec, 380 Anne-Marie Guerguerian, Daniela Guerreiro, Romain Guery, Anne Guillaumot, Laurent Guilleminault, 381 Thomas Guimard, Daniel Haber, Sheeba Hakak, Matthew Hall, Sophie Halpin, Ansley Hamer, Rebecca 382 Hamidfar, Terese Hammond, Hayley Hardwick, Kristen Harley, Ewen M. Harrison, Janet Harrison, 383 Leanne Hays, Jan Heerman, Lars Heggelund, Ross Hendry, Martina Hennessy, Aquiles Henriquez-384 Trujillo, Maxime Hentzien, Jaime Hernandez-Montfort, Astarini Hidayah, Dawn Higgins, Eibhilin 385 Higgins, Samuel Hinton, Ana Hipólito -Reis, Hiroaki Hiraiwa, Julian A. Hiscox, Antonia Ying Wai Ho, 386 Alexandre Hoctin, Isabelle Hoffmann, Oscar Hoiting, Rebecca Holt, Jan Cato Holter, Peter Horby, 387 Juan Pablo Horcajada, Koji Hoshino, Kota Hoshino, Catherine L. Hough, Jimmy Ming-Yang Hsu, Jean-388 Sébastien Hulot, Samreen Ijaz, Hajnal-Gabriela Illes, Hugo Inácio, Carmen Infante Dominguez, Elias 389 losifidis, Lacey Irvine, Sarah Isgett, Tiago Isidoro, Margaux Isnard, Junji Itai, Daniel Ivulich, Salma 390 Jaafoura, Julien Jabot, Clare Jackson, Nina Jamieson, Stéphane Jaureguiberry, Jeffrey Javidfar, Zabbe 391 Jean- Benoît, Florence Jego, Synne Jenum, Ruth Jimbo Sotomayor, Ruth Noemí Jorge García, Cédric

392 Joseph, Mark Joseph, Philippe Jouvet, Hanna Jung, Ouifiya Kafif, Florentia Kaguelidou, Sabina Kali, 393 Smaragdi Kalomoiri, Darshana Hewa Kandamby, Chris Kandel, Ravi Kant, Christiana Kartsonaki, 394 Daisuke Kasugai, Kevin Katz, Simreen Kaur Johal, Sean Keating, Andrea Kelly, Sadie Kelly, Lisa 395 Kennedy, Kalynn Kennon, Younes Kerroumi, Evelyne Kestelyn, Imrana Khalid, Antoine Khalil, Coralie 396 Khan, Irfan Khan, Michelle E Kho, Saye Khoo, Yuri Kida, Peter Kiiza, Anders Benjamin Kildal, Antoine 397 Kimmoun, Detlef Kindgen-Milles, Nobuya Kitamura, Paul Klenerman, Gry Kloumann Bekken, Stephen 398 Knight, Robin Kobbe, Malte Kohns Vasconcelos, Volkan Korten, Caroline Kosgei, Karolina Krawczyk, 399 Pavan Kumar Vecham, Deepali Kumar, Ethan Kurtzman, Demetrios Kutsogiannis, Konstantinos 400 Kyriakoulis, Erwan L'her, Marie Lachatre, Marie Lacoste, John G Laffey, Marie Lagrange, Fabrice 401 Laine, Marc Lambert, François Lamontagne, Marie Langelot-Richard, Eka Yudha Lantang, Marina 402 Lanza, Cédric Laouénan, Samira Laribi, Delphine Lariviere, Odile Launay, Yoan Lavie-Badie, Andrew 403 Law, Clément Le Bihan, Cyril Le Bris, Eve Le Coustumier, Georges Le Falher, Sylvie Le Gac, Quentin Le 404 Hingrat, Marion Le Maréchal, Soizic Le Mestre, Vincent Le Moing, Hervé Le Nagard, Paul Le Turnier, 405 Rafael León, Minh Le, Marta Leal Santos, Ema Leal, James Lee, Su Hwan Lee, Todd Lee, Gary 406 Leeming, Bénédicte Lefebvre, Laurent Lefebvre, Benjamin Lefevre, Francois Lellouche, Adrien 407 Lemaignen, Véronique Lemee, Gretchen Lemmink, Michela Leone, Quentin Lepiller, François-Xavier 408 Lescure, Olivier Lesens, Mathieu Lesouhaitier, Claire Levy-Marchal, Bruno Levy, Yves Levy, Gianluigi 409 Li Bassi, Janet Liang, Wei Shen Lim, Bruno Lina, Andreas Lind, Guillaume Lingas, Sylvie Lion-Daolio, 410 Keibun Liu, Antonio Loforte, Navy Lolong, Diogo Lopes, Dalia Lopez-Colon, Paul Loubet, Jean 411 Christophe Lucet, Carlos M. Luna, Olguta Lungu, Liem Luong, Dominique Luton, Ruth Lyons, Fredrik 412 Müller, Karl Erik Müller, Olavi Maasikas, Sarah Macdonald, Moïse Machado, Gabrielle Macheda, Juan 413 Macias Sanchez, Jai Madhok, Rafael Mahieu, Sophie Mahy, Lars Siegfrid Maier, Mylène Maillet, 414 Thomas Maitre, Maximilian Malfertheiner, Nadia Malik, Fernando Maltez, Denis Malvy, Marina 415 Mambert, Victoria Manda, Jose M. Mandei, Edmund Manning, Aldric Manuel, Ceila Maria Sant'Ana 416 Malague, Flávio Marino, Carolline De Araújo Mariz, Charbel Maroun Eid, Ana Margues, Catherine 417 Marquis, Brian Marsh, Laura Marsh, John Marshall, Celina Turchi Martelli, Guillaume Martin-Blondel,

418 Ignacio Martin-Loeches, Alejandro Martin-Quiros, Dori-Ann Martin, Emily Martin, Martin Martinot, 419 Caroline Martins Rego, Ana Martins, João Martins, Gennaro Martucci, Eva Miranda Marwali, Juan 420 Fernado Masa Jimenez, David Maslove, Sabina Mason, Moshe Matan, Daniel Mathieu, Mathieu 421 Mattei, Romans Matulevics, Laurence Maulin, Natalie Mc Evoy, Aine McCarthy, Anne McCarthy, 422 Colin McCloskey, Rachael McConnochie, Sherry McDermott, Sarah McDonald, Samuel McElwee, 423 Natalie McEvoy, Allison McGeer, Niki McGuinness, Kenneth A. McLean, Bairbre McNicholas, Edel 424 Meaney, Cécile Mear-Passard, Maggie Mechlin, Ferruccio Mele, Kusum Menon, France Mentré, 425 Alexander J. Mentzer, Noémie Mercier, Antoine Merckx, Blake Mergler, Laura Merson, António 426 Mesquita, Agnès Meybeck, Alison M. Meynert, Vanina Meyssonnier, Amina Meziane, Medhi Mezidi, 427 Céline Michelanglei, Vladislav Mihnovitš, Hugo Miranda Maldonado, Mary Mone, Asma Moin, David 428 Molina, Elena Molinos, Agostinho Monteiro, Claudia Montes, Giorgia Montrucchio, Sarah Moore, 429 Shona C. Moore, Lina Morales-Cely, Lucia Moro, Diego Rolando Morocho Tutillo, Ana Motos, Hugo 430 Mouquet, Clara Mouton Perrot, Julien Moyet, Jimmy Mullaert, Daniel Munblit, Derek Murphy, 431 Marlène Murris, Dimitra Melia Myrodia, Yohan N'guyen, Nadège Neant, Holger Neb, Nikita A 432 Nekliudov, Raul Neto, Emily Neumann, Bernardo Neves, Pauline Yeung Ng, Wing Yiu Ng, Orna Ni 433 Choileain, Alistair Nichol, Stephanie Nonas, Marion Noret, Lisa Norman, Alessandra Notari, Mahdad 434 Noursadeghi, Karolina Nowicka, Saad Nseir, Jose I Nunez, Elsa Nyamankolly, Max O'Donnell, Katie 435 O'Hearn, Conar O'Neil, Giovanna Occhipinti, Tawnya Ogston, Takayuki Ogura, Tak-Hyuk Oh, 436 Shinichiro Ohshimo, Budha Charan Singh Oinam, Ana Pinho Oliveira, João Oliveira, Piero Olliaro, 437 David S. Y. Ong, Wilna Oosthuyzen, Peter J.M. Openshaw, Claudia Milena Orozco-Chamorro, Andrés 438 Orquera, Javier Osatnik, Nadia Ouamara, Rachida Ouissa, Clark Owyang, Eric Oziol, Diana Póvoas, 439 Maïder Pagadov, Justine Pages, Mario Palacios, Massimo Palmarini, Giovanna Panarello, Prasan 440 Kumar Panda, Mauro Panigada, Nathalie Pansu, Aurélie Papadopoulos, Briseida Parra, Jérémie 441 Pasquier, Fabian Patauner, Luís Patrão, Christelle Paul, Mical Paul, Jorge Paulos, William A. Paxton, 442 Jean-François Payen, India Pearse, Giles J Peek, Florent Peelman, Nathan Peiffer-Smadja, Vincent 443 Peigne, Mare Pejkovska, Ithan D. Peltan, Rui Pereira, Daniel Perez, Thomas Perpoint, Antonio

444 Pesenti, Lenka Petroušová, Ventzislava Petrov-Sanchez, Gilles Peytavin, Scott Pharand, Michael 445 Piagnerelli, Walter Picard, Olivier Picone, Marie Piel-Julian, Carola Pierobon, Carlos Pimentel, Lionel 446 Piroth, Riinu Pius, Simone Piva, Laurent Plantier, Daniel Plotkin, Julien Poissy, Maria Pokorska-Spiewak, Sergio Poli, Georgios Pollakis, Jolanta Popielska, Douwe F. Postma, Pedro Povoa, Jeff Powis, 447 448 Sofia Prapa, Christian Prebensen, Jean-Charles Preiser, Vincent Prestre, Nicholas Price, Anton 449 Prinssen, Mark G. Pritchard, Lúcia Proença, Oriane Puéchal, Gregory Purcell, Luisa Quesada, Else 450 Quist-Paulsen, Mohammed Quraishi, Indrek Rätsep, Bernhard Rössler, Christian Rabaud, Marie 451 Rafig, Gabrielle Ragazzo, Fernando Rainieri, Nagarajan Ramakrishnan, Kollengode Ramanathan, 452 Blandine Rammaert, Christophe Rapp, Menaldi Rasmin, Cornelius Rau, Stanislas Rebaudet, Sarah 453 Redl, Brenda Reeve, Liadain Reid, Renato Reis, Jonathan Remppis, Martine Remy, Hanna Renk, 454 Liliana Resende, Anne-Sophie Resseguier, Matthieu Revest, Oleksa Rewa, Luis Felipe Reves, David 455 Richardson, Denise Richardson, Laurent Richier, Jordi Riera, Ana Lúcia Rios, Asgar Rishu, Patrick 456 Rispal, Karine Risso, Maria Angelica Rivera Nuñez, Nicholas Rizer, André Roberto, Stephanie Roberts, 457 David L. Robertson, Olivier Robineau, Ferran Roche-Campo, Paola Rodari, Simão Rodeia, Julia 458 Rodriguez Abreu, Emmanuel Roilides, Amanda Rojek, Juliette Romaru, Roberto Roncon-Albuquerque 459 Jr, Mélanie Roriz, Manuel Rosa-Calatrava, Michael Rose, Dorothea Rosenberger, Andrea Rossanese, 460 Bénédicte Rossignol, Patrick Rossignol, Carine Roy, Benoît Roze, Clark D. Russell, Steffi Ryckaert, 461 Aleksander Rygh Holten, Xavier Sánchez Choez, Isabela Saba, Musharaf Sadat, Nadia Saidani, 462 Leonardo Salazar, Gabriele Sales, Stéphane Sallaberry, Hélène Salvator, Angel Sanchez-Miralles, 463 Olivier Sanchez, Vanessa Sancho-Shimizu, Gyan Sandhu, Oana Sandulescu, Marlene Santos, Shirley 464 Sarfo-Mensah, Benjamine Sarton, Egle Saviciute, Parthena Savvidou, Joshua Scarsbrook, Tjard 465 Schermer, Arnaud Scherpereel, Marion Schneider, Stephan Schroll, Michael Schwameis, James Scott-466 Brown, Janet T. Scott, Nicholas Sedillot, Tamara Seitz, Caroline Semaille, Malcolm G. Semple, Eric 467 Senneville, Filipa Sequeira, Tânia Sequeira, Ellen Shadowitz, Mohammad Shamsah, Pratima Sharma, 468 Catherine A. Shaw, Victoria Shaw, Nisreen Shiban, Nobuaki Shime, Hiroaki Shimizu, Keiki Shimizu, 469 Sally Shrapnel, Hoi Ping Shum, Nassima Si Mohammed, Louise Sigfrid, Catarina Silva, Maria Joao

470 Silva, Wai Ching Sin, Vegard Skogen, Sue Smith, Benjamin Smood, Michelle Smyth, Morgane 471 Snacken, Dominic So, Monserrat Solis, Joshua Solomon, Tom Solomon, Emily Somers, Agnès 472 Sommet, Myung Jin Song, Rima Song, Tae Song, Michael Sonntagbauer, Edouard Soum, Maria Sousa 473 Uva, Marta Sousa, Vicente Souza-Dantas, Alexandra Sperry, Shiranee Sriskandan, Thomas 474 Staudinger, Stephanie-Susanne Stecher, Ymkje Stienstra, Birgitte Stiksrud, Adrian Streinu-Cercel, 475 Anca Streinu-Cercel, Samantha Strudwick, Ami Stuart, David Stuart, Asfia Sultana, Charlotte 476 Summers, Magdalena Surovcová Andrey A Svistunov, Konstantinos Syrigos, Jaques Sztajnbok, 477 Konstanty Szuldrzynski, François Téoulé, Shirin Tabrizi, Lysa Tagherset, Ewa Talarek, Sara Taleb, 478 Jelmer Talsma, Le Van Tan, Hiroyuki Tanaka, Taku Tanaka, Hayato Taniguchi, Coralie Tardivon, Pierre 479 Tattevin, M Azhari Taufik, Richard S. Tedder, João Teixeira, Marie-Capucine Tellier, Pleun Terpstra, 480 Olivier Terrier, Nicolas Terzi, Hubert Tessier-Grenier, Vincent Thibault, Simon-Djamel Thiberville, 481 Benoît Thill, A.A. Roger Thompson, Shaun Thompson, David Thomson, Emma C. Thomson, Duong 482 Bich Thuy, Ryan S. Thwaites, Peter S. Timashev, Jean-François Timsit, Bharath Kumar Tirupakuzhi 483 Vijayaraghavan, Maria Toki, Kristian Tonby, Rosario Maria Torres Santos-Olmo, Antoni Torres, 484 Margarida Torres, Théo Trioux, Huynh Trung Trieu, Cécile Tromeur, Ioannis Trontzas, Jonathan 485 Troost, Tiffany Trouillon, Christelle Tual, Sarah Tubiana, Helen Tuite, Lance C.W. Turtle, Pawel 486 Twardowski, Makoto Uchiyama, Roman Ullrich, Alberto Uribe, Asad Usman, Luís Val-Flores, Stijn Van 487 De Velde, Marcel Van Den Berge, Machteld Van Der Feltz, Nicky Van Der Vekens, Peter Van Der 488 Voort, Sylvie Van Der Werf, Marlice Van Dyk, Laura Van Gulik, Jarne Van Hattem, Steven Van 489 Lelyveld, Carolien Van Netten, Noémie Vanel, Henk Vanoverschelde, Charline Vauchy, Aurélie 490 Veislinger, Jorge Velazco, Sara Ventura, Annelies Verbon, César Vieira, Joy Ann Villanueva, Judit 491 Villar, Pierre-Marc Villeneuve, Andrea Villoldo, Nguyen Van Vinh Chau, Benoit Visseaux, Hannah 492 Visser, Aapeli Vuorinen, Fanny Vuotto, Chih-Hsien Wang, Jia Wei, Katharina Weil, Sanne Wesselius, 493 Murray Wham, Bryan Whelan, Nicole White, Aurélie Wiedemann, Keith Wille, Evert-Jan Wils, Ioannis 494 Xynogalas, Jacky Y Suen, Sophie Yacoub, Masaki Yamazaki, Yazdan Yazdanpanah, Cécile Yelnik, 495 Stephanie Yerkovich, Toshiki Yokoyama, Hodane Yonis, Paul Young, Saptadi Yuliarto, Marion Zabbe,

- 496 Kai Zacharowski, Maram Zahran, Maria Zambon, Alberto Zanella, Konrad Zawadka, Hiba Zayyad,
- 497 Alexander Zoufaly, David Zucman; The PETAL Network Investigators, The Western Australian Covid-
- 498 19 Research Response.
- 499 (Author contributions are listed in the supplementary material.)

500 Funding

501 This work was supported by the Department for International Development and Wellcome Trust 502 [215091/Z/18/Z]; the Bill and Melinda Gates Foundation [OPP1209135]. Country-specific support 503 was provided by the Canadian Institutes of Health Research Coronavirus Rapid Research Funding 504 Opportunity [OV2170359]; the Health Research Board Ireland [CTN Award 2014-012]; National 505 Institute for Health Research (NIHR) [award CO-CIN-01]; the Medical Research Council (MRC) [grant 506 MC PC 19059]; the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic 507 Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration 508 with Liverpool School of Tropical Medicine and the University of Oxford [award 200907]; NIHR HPRU 509 in Respiratory Infections at Imperial College London with PHE [award 200927]; Liverpool 510 Experimental Cancer Medicine Centre [grant reference C18616/A25153]; NIHR Biomedical Research 511 Centre at Imperial College London [IS-BRC-1215-20013]; EU Platform for European Preparedness 512 Against (Re-)emerging Epidemics (PREPARE) [FP7 project 602525]; National Institutes of Health (NIH) [UL1TR002240]; and NIHR Clinical Research Network infrastructure support. We acknowledge the 513 514 generous support of all ISARIC Partners who have contributed data and expertise to this analysis, with or without dedicated funding. The views expressed are those of the authors and not 515 necessarily those of the funders or institutions listed above. 516

517 Conflicts of Interest

518 M. Cheng declares grants from McGill Interdisciplinary Initiative in Infection and Immunity, and
519 Canadian Institutes of Health Research; and personal fees from GEn1E Lifesciences (as a member of

520 the scientific advisory board) and nplex biosciences (as a member of the scientific advisory board); 521 M. Cummings and M. O'Donnell participated as investigators for completed and ongoing clinical trials evaluating the efficacy and safety of remdesivir (sponsored by Gilead Sciences) and 522 523 convalescent plasma (sponsored by Amazon), in hospitalized patients with Covid-19 – support for 524 this work is paid to Columbia University; J. C. Holter declared grants from Research Council of 525 Norway [grant 312780], and Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, during the 526 conduct of the study; A.Kimmoun declared personal fees (payment for lectures) from Baxter, 527 Aguettant, Aspen; D. Kumar declared grants and personal fees from Roche, GSK and Merck, and 528 personal fees from Pfizer and Sanofi; F.X. Lescure declared personal fees (payment for lectures) from 529 Gilead, MSD; and travel/accommodation/meeting expenses from Astellas, Eumedica, MSD;bA. Pesenti declared personal fees from Maguet, Novalung/Xenios, Baxter, and Boehringer Ingelheim; 530 531 R.Tedder reports grants from MRC/UKRI during the conduct of the study, and has a patent United 532 Kingdom Patent Application No. 2014047.1 "SARS-CoV-2 antibody detection assay" issued; J. Troost 533 declared personal fees from General Electric and Procter and Gamble.

534 Acknowledgements

535 We are extremely grateful to the frontline clinical and research staff and volunteers, who collected this data in challenging circumstances, and the generosity of the patients and their families for their 536 individual contributions in these difficult times. This work uses data provided by patients and 537 538 collected by the health institutions and authorities in each country. In the UK, this study involves the National Health Service as part of their care and support #DataSavesLives. We also acknowledge the 539 support of Jeremy J Farrar, Nahoko Shindo, Devika Dixit, Nipunie Rajapakse, Andrew Davison, David 540 541 Barr, Lyndsey Castle, Martha Buckley, Debbie Malden, Katherine Newell, Kwame O'Neill, 542 Emmanuelle Denis, Claire Petersen, Scott Mullaney, Sue MacFarlane, Nicole Maziere, Julien 543 Martinez, Oslem Dincarslan, Annette Lake and the Irish Critical Care Trials Group. We appreciate the 544 strong collaboration of the WHO Clinical Data Platform Team, including Silvia Bertagnolio, Soe Soe

545 Thwin, and Janet Diaz.

References 546

547	1.	Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease
548	_	outbreak controllable. Proc Natl Acad Sci U S A 2004 ; 101(16): 6146-51.
549	2.	Clemency BM, Varughese R, Scheafer DK, et al. Symptom criteria for COVID-19 testing of
550		heath care workers. Acad Emerg Med 2020 ; 27(6): 469-74.
551	3.	Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China:
552		The mystery and the miracle. J Med Virol 2020 ; 92(4): 401-2.
553	4.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
554	F	coronavirus in Wuhan, China. Lancet 2020 ; 395(10223): 497-506.
555	5.	Wang G, Chen W, Jin X, Chen YP. Description of COVID-19 cases along with the measures
556	c	taken on prevention and control in Zhejiang, China. J Med Virol 2020 .
557	6.	Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N
558	_	Engl J Med 2020 ; 382(18): 1708-20.
559	7.	Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised
560		patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a
561		nationwide analysis of China. Eur Respir J 2020 ; 55(6): 2000562.
562	8.	Docherty AB, Harrison EM, Green CA, et al. Features of 20133 UK patients in hospital with
563		covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational
564		cohort study. BMJ 2020 ; 369: m1985.
565	9.	Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in patients
566		with severe acute respiratory coronavirus 2 infection: A cross-sectional study. Clin Infect Dis
567		2020 ; 71(15): 889-90.
568	10.	Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory
569		dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum
570		Allergy Rhinol 2020 ; 10(7): 806-13.
571	11.	World Health Organization. Global surveillance for COVID-19 caused by human infection
572		with COVID-19 virus: Interim guidance. Geneva, Switzerland: World Health Organization,
573		2020 .
574	12.	Centers for Disease Control and Prevention. Symptoms of coronavirus. Available at:
575		https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed
576		20 May 2020.
577	13.	Public Health England. COVID-19: investigation and initial clinical management of possible
578		cases. Available at: https://www.gov.uk/government/publications/wuhan-novel-
579		coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-
580		management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection. Accessed 20
581		May 2020.
582	14.	, Manoharan L, Cattrall JWS, Harris C, et al. Early clinical characteristics of Covid-19: scoping
583		review. MedRxiv 2020 : 2020.07.31.20165738. [Preprint]. August 4, 2020 [cited 7 August
584		2020]. Available from https://doi.org/10.1101/2020.07.31.20165738.
585	15.	International Severe Acute Respiratory and Emerging Infection Consortium, World Health
586		Organization. ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections,
587		version 3.2: ISARIC, 2020 .
588	16.	International Severe Acute Respiratory and Emerging Infection Consortium. COVID-19 CRF.
589	10.	Available at: https://isaric.tghn.org/COVID-19-CRF/. Accessed 21 August 2020.
590	17.	Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2
590 591	17.	pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet
591 592		Respir Med 2020 ; 8(5): 475-81.
727		NESHI WEU 2020, 0(3). 4/3-01.

502	10	Zhou E. Vu T. Du D. et al. Clinical course and visk featows for montality of adult invotionts with
593	18.	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with
594	10	COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 ; 395(10229): 1054-62.
595	19.	Dunning JW, Merson L, Rohde GGU, et al. Open source clinical science for emerging
596	20	infections. Lancet Infect Dis 2014 ; 14(1): 8-9.
597	20.	ISARIC clinical characterisation group. Global outbreak research: harmony not hegemony.
598		Lancet Infect Dis 2020 ; 20(7): 770-2.
599	21.	Hall M, Pritchard M, Dankwa E, et al. ISARIC COVID-19 clinical data report: 8 June 2020.
600		MedRxiv 2020 : 2020.07.17.20155218 [Preprint]. July 25, 2020 [cited 7 August 2020].
601		Available from <u>https://doi.org/10.1101/2020.07.17.20155218</u> .
602	22.	ISARIC 4C. ISARIC 4C protocols. Available at: <u>https://isaric4c.net/protocols/</u> . Accessed 26
603		August 2020.
604	23.	COVID-19 Critical Care Consortium. COVID-19 Critical Care Consortium Trial Documents.
605		Available at: https://www.elso.org/COVID19/ECMOCARD.aspx . Accessed 26 August 2020.
606	24.	Munblit D, Nekliudov NA, Bugaeva P, et al. StopCOVID cohort: An observational study of
607		3,480 patients admitted to the Sechenov University hospital network in Moscow city for
608		suspected COVID-19 infection. Clin Infect Dis 2020.
609	25.	Larsen K, Merlo J. Appropriate assessment of neighborhood effects on individual health:
610		integrating random and fixed effects in multilevel logistic regression. Am J Epidemiol 2005;
611		161(1): 81-8.
612	26.	Lauretani F, Ravazzoni G, Roberti MF, et al. Assessment and treatment of older individuals
613		with COVID 19 multi-system disease: Clinical and ethical implications. Acta Biomed 2020;
614		91(2): 150-68.
615	27.	Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison
616		with young and middle-aged patients. J Infect 2020 ; 80(6): e14-e8.
617	28.	Jung YJ, Yoon JL, Kim HS, Lee AY, Kim MY, Cho JJ. Atypical clinical presentation of geriatric
618		syndrome in elderly patients with pneumonia or coronary artery disease. Ann Geriatr Med
619		Res 2018 ; 21(4): 158-63.
620	29.	Wester AL, Dunlop O, Melby KK, Dahle UR, Wyller TB. Age-related differences in symptoms,
621		diagnosis and prognosis of bacteremia. BMC Infect Dis 2013; 13: 346.
622	30.	Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med 2020 ; 382(17):
623		1663-5.
624	31.	Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better
625		prognosis than adults. Acta Paediatr 2020 ; 109: 1088-95.
626	32.	Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people
627		admitted to hospital with covid-19 in United Kingdom: prospective multicentre
628		observational cohort study. BMJ 2020 ; 370: m3249.
629	33.	Millar JE, Neyton L, Seth S, et al. Robust, reproducible clinical patterns in hospitalised
630		patients with COVID-19. MedRxiv 2020: 2020.08.14.20168088. [Preprint]. August 16, 2020
631		[cited 2 September 2020]. Available from: https://doi.org/10.1101/2020.08.14.20168088
632	34.	Sierpiński R, Pinkas J, Jankowski M, et al. Sex differences in the frequency of gastrointestinal
633		symptoms and olfactory or taste disorders in 1942 nonhospitalized patients with coronavirus
634		disease 2019 (COVID-19). Pol Arch Intern Med 2020 ; 130(6): 501-5.
635	35.	World Bank. World Bank country and lending groups. Available at:
636		https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-
637		and-lending-groups.
620		

Tables 640

Table 1. Patient demographics 641

		Sex	
Overall	Female	Male	
n = 60 161	n = 25 487	n = 34 674	P-value
70 [54, 82]	72 [55, 83]	68 [54 <i>,</i> 80]	<0.001
			<0.001
514 (0.9)	221 (0.9)	293 (0.8)	
523 (0.9)	221 (0.9)	302 (0.9)	
1973 (3.3)	873 (3.4)	1100 (3.2)	
3211 (5.3)	1452 (5.7)	1759 (5.1)	
5018 (8.3)	1967 (7.7)	3051 (8.8)	
8584 (14.3)	3280 (12.9)	5304 (15.3)	
9882 (16.4)	3702 (14.5)	6180 (17.8)	
12351 (20.5)	4924 (19.3)	7427 (21.4)	
13495 (22.4)	6202 (24.3)	7293 (21.0)	
4610 (7.7)	2645 (10.4)	1965 (5.7)	
			<0.001
3252 (5.4)	1117 (4.4)	2135 (6.2)	
55453 (92.2)	23768 (93.3)	31685 (91.4)	
162 (0.3)	67 (0.3)	95 (0.3)	
91 (0.2)	35 (0.1)	56 (0.2)	
926 (1.5)	413 (1.6)	513 (1.5)	
267 (0.4)	83 (0.3)	184 (0.5)	
10 (0.0)	4 (0.0)	6 (0.0)	
			<0.001
54888 (91.2)	23439 (92.0)	31449 (90.7)	
5003 (8.3)	1964 (7.7)	3039 (8.8)	
270 (0.4)	84 (0.3)	186 (0.5)	
	n = 60 161 70 [54, 82] 514 (0.9) 523 (0.9) 1973 (3.3) 3211 (5.3) 5018 (8.3) 8584 (14.3) 9882 (16.4) 12351 (20.5) 13495 (22.4) 4610 (7.7) 3252 (5.4) 55453 (92.2) 162 (0.3) 91 (0.2) 926 (1.5) 267 (0.4) 10 (0.0) 54888 (91.2) 5003 (8.3)	n = 60 161n = 25 48770 [54, 82]72 [55, 83]514 (0.9)221 (0.9)523 (0.9)221 (0.9)1973 (3.3)873 (3.4)3211 (5.3)1452 (5.7)5018 (8.3)1967 (7.7)8584 (14.3)3280 (12.9)9882 (16.4)3702 (14.5)12351 (20.5)4924 (19.3)13495 (22.4)6202 (24.3)4610 (7.7)2645 (10.4)3252 (5.4)1117 (4.4)55453 (92.2)23768 (93.3)162 (0.3)67 (0.3)91 (0.2)35 (0.1)926 (1.5)413 (1.6)267 (0.4)83 (0.3)10 (0.0)4 (0.0)54888 (91.2)23439 (92.0)5003 (8.3)1964 (7.7)	OverallFemaleMale $n = 60 161$ $n = 25 487$ $n = 34 674$ 70 [54, 82]72 [55, 83]68 [54, 80]514 (0.9)221 (0.9)293 (0.8)523 (0.9)221 (0.9)302 (0.9)1973 (3.3)873 (3.4)1100 (3.2)3211 (5.3)1452 (5.7)1759 (5.1)5018 (8.3)1967 (7.7)3051 (8.8)8584 (14.3)3280 (12.9)5304 (15.3)9882 (16.4)3702 (14.5)6180 (17.8)12351 (20.5)4924 (19.3)7427 (21.4)13495 (22.4)6202 (24.3)7293 (21.0)4610 (7.7)2645 (10.4)1965 (5.7)3252 (5.4)1117 (4.4)2135 (6.2)55453 (92.2)23768 (93.3)31685 (91.4)162 (0.3)67 (0.3)95 (0.3)91 (0.2)35 (0.1)56 (0.2)926 (1.5)413 (1.6)513 (1.5)267 (0.4)83 (0.3)184 (0.5)10 (0.0)4 (0.0)6 (0.0)54888 (91.2)23439 (92.0)31449 (90.7)5003 (8.3)1964 (7.7)3039 (8.8)

IQR, interquartile range

* Data are number (percent within columns) unless specified otherwise

+ According to World Bank classification [35]

642

644 Table 2. Symptoms at presentation to hospital with Covid-19

			Sex		
	Overall	Female	Male	P-	Missing
Variable*	n = 60 161	n = 25 487	n = 34 674	value	data†
Fever	41109 (68.4)	16663 (65.4)	24446 (70.5)	< 0.001	34 (0.1)
Cough	40930 (68.1)	16696 (65.6)	24234 (69.9)	<0.001	50 (0.1)
Shortness of breath	37577 (62.5)	15450 (60.7)	22127 (63.9)	<0.001	78 (0.1)
Fatigue	23319 (38.8)	9889 (38.9)	13430 (38.8)	0.903	120 (0.2)
Confusion	13732 (24.1)	6108 (25.1)	7624 (23.4)	< 0.001	3196 (5.3)
Diarrhoea	10061 (16.8)	4565 (17.9)	5496 (15.9)	< 0.001	114 (0.2)
Nausea and vomiting	9891 (16.5)	5099 (20.0)	4792 (13.8)	< 0.001	110 (0.2)
Muscle pains	9472 (15.8)	3952 (15.5)	5520 (16.0)	0.167	124 (0.2)
Anorexia	613 (13.3)	243 (12.2)	370 (14.1)	0.065	55552 (92.3)
Chest pain	6953 (11.6)	3084 (12.1)	3869 (11.2)	< 0.001	118 (0.2)
Headache	6154 (10.3)	2830 (11.1)	3324 (9.6)	< 0.001	136 (0.2)
Abdominal pain	5305 (8.8)	2597 (10.2)	2708 (7.8)	< 0.001	123 (0.2)
Sore throat	4880 (8.1)	2135 (8.4)	2745 (8.0)	0.046	243 (0.4)
Severe dehydration	3451 (7.2)	1562 (7.6)	1889 (6.9)	0.005	12166 (20.2)
Wheeze	3845 (6.4)	1790 (7.0)	2055 (6.0)	< 0.001	246 (0.4)
Joint pains	3229 (5.4)	1459 (5.7)	1770 (5.1)	0.001	141 (0.2)
Altered sense of taste	2011 (5.2)	924 (5.5)	1087 (5.0)	0.014	21598 (35.9)
Altered sense of smell	1733 (4.5)	819 (4.9)	914 (4.2)	0.001	21483 (35.7)
Unable to walk	220 (4.4)	83 (3.8)	137 (4.7)	0.145	55106 (91.6)
Rhinorrhoea	2382 (4.0)	1041 (4.1)	1341 (3.9)	0.193	244 (0.4)
Skin ulcer	978 (1.9)	489 (2.2)	489 (1.6)	< 0.001	7924 (13.2)
Haemorrhage	993 (1.7)	429 (1.7)	564 (1.6)	0.625	249 (0.4)
Seizure	775 (1.4)	352 (1.4)	423 (1.3)	0.147	3221 (5.4)
Lower chest wall indraw	ing				
	688 (1.2)	235 (1.0)	453 (1.4)	< 0.001	3349 (5.6)
Rash	694 (1.2)	287 (1.1)	407 (1.2)	0.612	130 (0.2)
Lymphadenopathy	307 (0.5)	147 (0.6)	160 (0.5)	0.081	3340 (5.6)
Conjunctivitis	251 (0.4)	111 (0.4)	140 (0.4)	0.599	252 (0.4)
Ear pain	201 (0.4)	107 (0.5)	94 (0.3)	0.002	5275 (8.8)
Composite categories					314 (0.5)‡
Fever plus one of cough	or shortness of bi	reath			
	35394 (59.1)	14174 (55.9)	21220 (61.5)	< 0.001	
Fever plus one of cough,	rhinorrhoea, sho	rtness of breath	, sore throat, w	heeze	
	36006 (60.2)	14466 (57.0)	21540 (62.5)	< 0.001	
Cough or fever	50985 (85.2)	21033 (82.9)	29952 (86.9)	<0.001	
One or more of cough, sl	hortness of breat	h, fever, muscle	pain, sore throa	at	
	55198 (92.2)	22982 (90.6)	32216 (93.4)	<0.001	
* Data are number (perc	ent of patients w	ith non-missing	data within colu	ımns) unle	ess specified
otherwise					
+Number (percent of all	patients)				
‡ Patients missing any sy	mptom included i	n these criteria	are omitted from	n the com	nosite

‡Patients missing any symptom included in these criteria are omitted from the composite categories

	Age group (years)											
	Overall	0-	10-	20-	30–	40-	50-	60-	70-	80-	90-	Missing
Symptom*	n = 4649	n = 41	n = 74	n = 178	n = 188	n = 183	n = 309	n = 494	n = 981	n = 1542	n = 659	data
Confusion	2158 (48.8)	5 (12.5)	3 (8.3)	7 (7.3)	11 (7.9)	26 (16.0)	62 (21.6)	178 (37.0)	528 (54.2)	897 (58.2)	441 (66.9)	230 (4.9
Fatigue	1186 (25.5)	10 (24.4)	6 (8.1)	18 (10.1)	24 (12.8)	29 (15.8)	79 (25.6)	137 (27.7)	276 (28.1)	452 (29.3)	155 (23.5)	0 (0.0
Nausea and vomiting	1040 (22.4)	17 (41.5)	22 (29.7)	42 (23.6)	64 (34.0)	76 (41.5)	99 (32.0)	131 (26.5)	216 (22.0)	270 (17.5)	103 (15.6)	0 (0.0
Abdominal pain	844 (18.2)	6 (14.6)	21 (28.4)	49 (27.5)	71 (37.8)	54 (29.5)	87 (28.2)	117 (23.7)	173 (17.6)	195 (12.6)	71 (10.8)	1 (0.0
Diarrhoea	631 (13.6)	7 (17.1)	6 (8.1)	22 (12.4)	21 (11.2)	29 (15.8)	49 (15.9)	97 (19.6)	148 (15.1)	187 (12.1)	65 (9.9)	1 (0.0
Severe dehydration	521 (12.7)	3 (9.1)	2 (5.9)	3 (4.1)	2 (1.8)	9 (6.8)	19 (7.6)	43 (9.9)	121 (13.2)	225 (15.2)	94 (14.7)	541 (11.6
Headache	300 (6.5)	1 (2.4)	6 (8.1)	32 (18.0)	27 (14.4)	32 (17.5)	24 (7.8)	45 (9.1)	53 (5.4)	54 (3.5)	26 (4.0)	2 (0.0
Chest pain	295 (6.3)	0 (0.0)	0 (0.0)	8 (4.5)	11 (5.9)	19 (10.4)	49 (15.9)	49 (9.9)	46 (4.7)	83 (5.4)	30 (4.6)	0 (0.0
Haemorrhage	259 (5.6)	0 (0.0)	1 (1.4)	6 (3.4)	11 (5.9)	14 (7.7)	15 (4.9)	25 (5.1)	48 (4.9)	95 (6.2)	44 (6.7)	1 (0.0
Joint pain	197 (4.2)	1 (2.4)	3 (4.1)	2 (1.1)	5 (2.7)	7 (3.8)	7 (2.3)	16 (3.2)	33 (3.4)	86 (5.6)	37 (5.6)	1 (0.0
Seizure	181 (4.1)	5 (12.5)	3 (8.3)	6 (6.2)	7 (5.0)	13 (8.0)	17 (5.9)	27 (5.6)	35 (3.6)	52 (3.4)	16 (2.4)	230 (4.9
Skin ulcer	169 (4.0)	1 (3.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.0)	10 (3.6)	12 (2.6)	49 (5.2)	57 (3.8)	37 (5.7)	379 (8.2
Altered sense of smell	118 (3.3)	0 (0.0)	14 (19.4)	40 (25.8)	24 (15.2)	13 (8.8)	8 (3.4)	10 (2.6)	2 (0.3)	7 (0.6)	0 (0.0)	1029 (22.1
Rhinorrhoea	137 (2.9)	2 (4.9)	21 (28.4)	44 (24.7)	27 (14.4)	18 (9.8)	11 (3.6)	8 (1.6)	1 (0.1)	2 (0.1)	3 (0.5)	0 (0.0
Altered sense of	74 (2.0)	1 (2.9)	4 (5.6)	23 (14.8)	9 (5.7)	7 (4.8)	1 (0.4)	7 (1.8)	8 (1.1)	11 (0.9)	3 (0.6)	1029 (22.1
taste												
Rash	80 (1.7)	6 (14.6)	3 (4.1)	2 (1.1)	2 (1.1)	5 (2.7)	6 (1.9)	13 (2.6)	18 (1.8)	17 (1.1)	8 (1.2)	2 (0.0
Wheeze	62 (1.3)	0 (0.0)	0 (0.0)	1 (0.6)	0 (0.0)	0 (0.0)	3 (1.0)	7 (1.4)	13 (1.3)	26 (1.7)	12 (1.8)	0 (0.0

Table 3. Symptoms reported for patients meeting none of the clinical case definitions

650 Figure legends

651	Figure 1. Flow of participants in this analysis.
652	4C, Coronavirus Clinical Characterisation Consortium; CCC, Critical Care Consortium; ISARIC,
653	International Severe Acute Respiratory and emerging Infection Consortium; REDCap, Research
654	Electronic Data Capture; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.
655	
656	
657	Figure 2. Age-specific prevalence of symptoms at hospital admission.
658	
659	
660	Figure 3. Proportions meeting clinical criteria at hospital admission stratified by 10-year age band.
661	Black boxes show the proportion of individuals, with error bars showing 95% confidence intervals
662	calculated using the Clopper–Pearson method. The size of each box is inversely proportional to the
663	variance, so larger boxes indicate greater certainty. Grey boxes with 95% confidence intervals show
664	the proportions in the sensitivity analysis excluding patients recruited in the United Kingdom.
665	'Respiratory symptom' is any of cough, rhinorrhoea, shortness of breath, sore throat or wheeze.
666	Patients missing a symptom included in any criteria are excluded from all four plots.
667	
668	
669	Figure 4. Odds of symptoms among patients admitted to hospital with Covid-19, stratified by age
670	and sex.
671	Each plot is the result of a logistic regression with a symptom as an outcome. Fixed effects of age in
672	ten-year bands (baseline group 50–60 years) and sex are shown in black boxes with 95% confidence
673	intervals. The size of each square is inversely proportional to the variance of the log odds ratio, so
674	larger boxes indicate greater certainty. Clustering by country is included as a random intercept and

675 heterogeneity is depicted by circles showing the median odds ratio.

676

677

678 Figure 5. Age- and sex- specific odds of meeting clinical definitions among patients admitted to

- 679 hospital with Covid-19, stratified by age and sex.
- Each plot is the result of a logistic regression with a composite group of symptoms as an outcome.
- 681 Fixed effects of age in ten-year bands (baseline group 50–60 years) and sex are shown in black boxes
- 682 with 95% confidence intervals. The size of each square is inversely proportional to the variance of
- the log odds ratio, so larger boxes indicate greater certainty. Clustering by country is included as a
- random intercept and heterogeneity is depicted by circles showing the median odds ratio.
- 685 'Respiratory symptom' is any of cough, rhinorrhoea, shortness of breath, sore throat or wheeze.
- 686 Patients missing a symptom included in any criteria are excluded from all four plots.









